Search
Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
Read moreChairs and members
Chair (2024–2027)
Elizabeth Macintyre, Hôpital Necker-Enfants Malades et Université Paris, France
Vice-Chair (2024–2027)
Margarita Guenova, National Specialised Hospital for Active Treatment of Haematological Diseases, Belgium
Steering Committee (2024–2027)
Monika Brüggemann, University Hospital Kiel, Germany (ESHLO)
Francesco Buccisano, Tor Vergata University of Rome, Italy (SWG on Diagnosis…
Publications
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld…
Invitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“
For more information, please find the full invitation here
Read moreResearch Grants process explained
After creating the account, you can choose which project to select in the upper left corner. Be sure to select the one for applicants.
Read moreIbrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.
Read morePomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- »